TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an announcement.
Shanghai Henlius Biotech, Inc. has announced an extraordinary general meeting scheduled for December 31, 2025, to consider the approval of the Sinopharm Distribution Framework Agreement (2025 Renewal). This agreement, if approved, will facilitate continued collaboration with Sinopharm Group Co. Ltd., potentially enhancing the company’s distribution capabilities and market reach in the pharmaceutical sector.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of high-quality and affordable biologic medicines. The company operates in the biopharmaceutical industry, providing innovative therapeutic solutions primarily in the fields of oncology, autoimmune diseases, and ophthalmology.
Average Trading Volume: 1,465,995
Technical Sentiment Signal: Buy
Current Market Cap: HK$37.77B
For an in-depth examination of 2696 stock, go to TipRanks’ Overview page.